Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY19 results · Oct–Dec 2018
Marksans Pharma reported revenue from operations of ₹248.37 crore and net profit of ₹25.13 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 248.37 | — | — | 269.04 | −7.7% |
| Other income | 0.16 | — | — | (0.80) | Turned profit |
| Total income | 248.52 | — | — | 268.24 | −7.4% |
| Profit before tax | 29.55 | — | — | 27.72 | +6.6% |
| Net profit for the period | 25.13 | — | — | 20.57 | +22.2% |
| EPS, basic (₹) | 0.60 | — | — | 0.48 | +25.0% |
| Net margin (%) | 10.1 | — | 7.6 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 125.19 | — | — | 114.65 | +9.2% |
| Other income | 0.12 | — | — | 2.80 | −95.8% |
| Total income | 125.31 | — | — | 117.45 | +6.7% |
| Profit before tax | 13.98 | — | — | 16.54 | −15.5% |
| Net profit for the period | 11.78 | — | — | 12.34 | −4.5% |
| EPS, basic (₹) | 0.29 | — | — | 0.30 | −3.3% |
| Net margin (%) | 9.4 | — | 10.8 |
Consolidated
- Filed with BSE
- 09 Feb 2019, 17:50 IST
- Board meeting
- 08 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2019, 17:50 IST
- Board meeting
- 08 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE